EFFECTS OF CALCIUM-CHANNEL BLOCKERS ON THE DEVELOPMENT OF EARLY RAT POSTIMPLANTATION EMBRYOS IN CULTURE

被引:22
作者
STEIN, G [1 ]
SRIVASTAVA, MK [1 ]
MERKER, HJ [1 ]
NEUBERT, D [1 ]
机构
[1] FREE UNIV BERLIN,INST TOXIKOL & EMBRYOPHARMAKOL,GARYSTR 5,W-1000 BERLIN 33,GERMANY
关键词
Calcium channel blockers; Diltiazem; Gallopamil; In vitro; Nifedipine; Nimodipine; Nitrendipine; Rat whole-embryo culture; Verapamil;
D O I
10.1007/BF01974690
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Rat embryos (9.5-day-old) were cultured for 48 h in the presence of nifedipine (NIF), nimodipine (NIM), nitrendipine (NIT), gallopamil HCl (GAL), verapamil HCl (VER) and diltiazem HCl (DIL). The effects on growth and morphogenetic differentiation in vitro were monitored. Dose-response relationships were evaluated, including an assessment of the "no-observed-effect-level" (NOEL) or the "lowest-observed-effect-level" (LOEL), and the lowest concentration tested inducing abnormalities in 100% of the embryos ("100% EL"). The morphological alterations observed at the highest concentrations were very similar for all six drugs. The abnormalities concerned yolk sac circulation and morphology, as well as heartbeat, the morphology of the heart, head, neural tube, or fore-limbs, and the shape of the embryo. The abnormal embryos were also growth retarded (decrease in protein content and crown-rump length). Interference with calcium channel functions seems to represent an interesting model for studying a special kind of abnormal prenatal development, especially the differentiation of certain mesenchymal structures. The concentration ranges between NOELs and 100% ELs were found to be: NIM=0.1-1 Μg/ml; NIT and VER=1-10 Μg/ml; DIL=1-30 Μg/ml, and LOELs-100%ELs were: GAL=1-10 Μg/ml; NIF=10-30 Μg/ml. © 1990 Springer-Verlag.
引用
收藏
页码:623 / 638
页数:16
相关论文
共 48 条
[1]  
Ariyuki F, 1975, Okajimas Folia Anat Jpn, V52, P103
[2]  
BELLEMANN P, 1982, ARZNEIMITTEL-FORSCH, V32-1, P361
[3]  
BLOEDOW D C, 1980, Pharmacologist, V22, P192
[4]  
BOLGER GT, 1983, J PHARMACOL EXP THER, V225, P291
[5]  
BUHLER V, 1984, NAUNYNSCHMIEDEBERG S, V325, pR86
[6]  
CABOV AN, 1984, TERATOLOGY, V29, pA21
[7]   NIFEDIPINE AS A 2ND LINE ANTIHYPERTENSIVE DRUG IN PREGNANCY [J].
CONSTANTINE, G ;
BEEVERS, DG ;
REYNOLDS, AL ;
LUESLEY, DM .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1987, 94 (12) :1136-1142
[8]   NIFEDIPINE - INDIVIDUAL-RESPONSES AND CONCENTRATION-EFFECT RELATIONSHIPS [J].
DONNELLY, R ;
ELLIOTT, HL ;
MEREDITH, PA ;
KELMAN, AW ;
REID, JL .
HYPERTENSION, 1988, 12 (04) :443-449
[9]   NIFEDIPINE KINETICS IN THE RAT AND RELATIONSHIP BETWEEN ITS SERUM CONCENTRATIONS AND UTERINE AND CARDIOVASCULAR EFFECTS [J].
DOWNING, SJ ;
HOLLINGSWORTH, M .
BRITISH JOURNAL OF PHARMACOLOGY, 1988, 95 (01) :23-32
[10]   PHARMACOKINETICS OF (+)-VERAPAMIL, (-)-VERAPAMIL AND (+/-)-VERAPAMIL AFTER INTRAVENOUS ADMINISTRATION [J].
EICHELBAUM, M ;
MIKUS, G ;
VOGELGESANG, B .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 17 (04) :453-458